Articles related to COVID-19

The current real-world cohort study examines long-term survival outcomes in the 5 years after a COVID-19 hospitalization for adults with a solid malignancy. The study assessed the impact of vaccination status, vaccine platform, primary tumor site, and cancer treatment.

Genomic analyses revealed that all circulating strains were descendants of the Omicron JN.1 variant, “representing the first season without a SARS-CoV-2 strain replacement since the beginning of the COVID-19 pandemic.”

Dr. Joseph Wu, the study’s lead author and director of the Stanford Cardiovascular Institute: “These two cytokines cause inflammation to the blood vessels. They could cause inflammation to the heart.”

Pharmacists’ ability to provide off-label vaccines may be severely constrained… IDSA calls on insurers to continue covering COVID vaccines consistent with multiple medical society recommendations.

The more targeted vaccine formulation allows for administration of a smaller mRNA dose (10 mcg/0.2 mL) while achieving “higher seroresponse rates and geometric mean neutralizing antibody titer levels.”

Higher vaccine efficacy (13.5% [95% CI, -7.7, 30.6]) was observed with mNexspike vs the comparator in individuals aged 65 years and older.